-+ 0.00%
-+ 0.00%
-+ 0.00%

Novogenia nine-month EBITDA loss widens 47% to EUR 5.6 million

PUBT·11/20/2026 09:01:04
Listen to the news
Novogenia nine-month EBITDA loss widens 47% to EUR 5.6 million
  • Novogenia’s nine-month 2026 EBIT loss widened 26% to EUR 7.3 million, while revenue rose to EUR 43 million.
  • Third-quarter revenue jumped 27% to EUR 17.4 million, driven by expanded pharmaceutical and medical products trading offerings.
  • The quarterly loss after tax totaled EUR 400,000, limited by a positive financial result of EUR 2.2 million.
  • An expanded methylation test launched with US partner 10X Health in August, while production secured halal certification for Middle Eastern expansion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2438986_de) on November 20, 2026, and is solely responsible for the information contained therein.